Aharon Schwartz insider trades
Open-market stock purchases and sales by Aharon Schwartz, Director at Protalix BioTherapeutics, Inc, from SEC Form 4 filings since May 8, 2018.
Track record: 100% of 3 scored buys are up 5% or more since purchase, averaging +49%.